Sanem Tercan Avcı
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sanem Tercan Avcı has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
Neşe Atabey
İzmir Biomedicine and Genome Center Biobank and Biomolecular Resources Platform İzmir Türkiye
2 shared publicationsBeste Özkalay
İzmir Biomedicine and Genome Center Biobank and Biomolecular Resources Platform İzmir Türkiye
1 shared publication- Burcu Sengez
Izmir Biomedicine and Genome Center, Dokuz Eylül University Health Campus, Balçova, Izmir, Turkey
1 shared publication - Hani Alotaibi
Izmir International Biomedicine and Genome Institute, Dokuz Eylül University, Mithatpasa Cad. No 58/5, 35340, Izmir, Türkiye.
1 shared publication - Huma Shehwana
Department of Biological Sciences, National University of Medical Sciences, Rawalpindi 46000, Pakistan
1 shared publication - Ilkin Aygün
Centre for Advanced Technologies, Adam Mickiewicz University, Poznań, Poland
1 shared publication
Latest Publications
- Open Access
- 22 October 2025
- Published by Galenos Yayinevi in Inherited Metabolic Disorders and Nutrition
Biobanks and Their Contribution to the Field of Rare Diseases: Current Landscape, Challenges, and Future Directions
Biobanks and Their Contribution to the Field of Rare Diseases: Current Landscape, Challenges, and Future Directions - Inherited Metabolic Disorders and Nutrition
- 22 October 2025
- Published by Galenos Yayinevi in Inherited Metabolic Disorders and Nutrition
Open AccessBiobanks and Their Contribution to the Field of Rare Diseases: Current Landscape, Challenges, and Future Directions
Biobanks and Their Contribution to the Field of Rare Diseases: Current Landscape, Challenges, and Future Directions - Inherited Metabolic Disorders and Nutrition
- 25 June 2024
- Published by SAGE Publications in Biopreservation and Biobanking
- Vol. 22 (3) , 217-224
Biobank Education for Future Physicians: Training Medical Students Through Student Research Association Networks
Research biobanks have become crucial collaborators in a variety of basic and clinical research projects with comprehensive biological sample collection and associated data storage. Medical students, who are the most important stakeholders of biobanks as future physicians, need to be trained in biobanking; however, there is no consensus on how to include it in formal education. This study aimed to determine and increase awareness among medical students regarding biobanks through peer training organized online by medical student research association networks. Volunteer medical or graduate students were trained by biobank professionals at the Izmir Biomedicine and Genome Center (IBG) biobank for 6–9 months. Then, a biobank event was planned by these trainees, the Ege Scientific Research Team (ESRT), and IBG-Biobank with the support of The Biobanking and BioMolecular Resources Research Infrastructure (BBMRI) Turkey. The study reached students of 46 different medical faculties. Before the event, students' level of knowledge about biobanks was identified using a pre-event questionnaire ( n = 239). Following 2 days (4 main sessions) of online events, a post-event questionnaire was administered to event participants ( n = 110) and 80.9% of them answered ( n = 89). The pre-event survey revealed that only 34.3% of the medical students had heard of the term “Biobank” in Turkey. After the event, medical students were significantly more enthusiastic about putting effort into biobanking and using and sharing stored biobank samples of their patients compared with the pre-event ( p < 0.0001). Moreover, 92% of the students stated that they would consider attending an advanced course in biobanking. In conclusion, the current study demonstrates that extracurricular courses with peer learning methods coordinated with medical student associations can be valuable in increasing future physicians' awareness and knowledge of biobanking.
- 25 June 2024
- Published by SAGE Publications in Biopreservation and Biobanking
- Vol. 22 (3) , 217-224
Biobank Education for Future Physicians: Training Medical Students Through Student Research Association Networks
Research biobanks have become crucial collaborators in a variety of basic and clinical research projects with comprehensive biological sample collection and associated data storage. Medical students, who are the most important stakeholders of biobanks as future physicians, need to be trained in biobanking; however, there is no consensus on how to include it in formal education. This study aimed to determine and increase awareness among medical students regarding biobanks through peer training organized online by medical student research association networks. Volunteer medical or graduate students were trained by biobank professionals at the Izmir Biomedicine and Genome Center (IBG) biobank for 6–9 months. Then, a biobank event was planned by these trainees, the Ege Scientific Research Team (ESRT), and IBG-Biobank with the support of The Biobanking and BioMolecular Resources Research Infrastructure (BBMRI) Turkey. The study reached students of 46 different medical faculties. Before the event, students' level of knowledge about biobanks was identified using a pre-event questionnaire ( n = 239). Following 2 days (4 main sessions) of online events, a post-event questionnaire was administered to event participants ( n = 110) and 80.9% of them answered ( n = 89). The pre-event survey revealed that only 34.3% of the medical students had heard of the term “Biobank” in Turkey. After the event, medical students were significantly more enthusiastic about putting effort into biobanking and using and sharing stored biobank samples of their patients compared with the pre-event ( p < 0.0001). Moreover, 92% of the students stated that they would consider attending an advanced course in biobanking. In conclusion, the current study demonstrates that extracurricular courses with peer learning methods coordinated with medical student associations can be valuable in increasing future physicians' awareness and knowledge of biobanking.
- 22 November 2021
- Published by Springer Nature in Journal of Gastrointestinal Cancer
- Vol. 52 (4) , 1232-1247
Role of Biobanks for Cancer Research and Precision Medicine in Hepatocellular Carcinoma
Introduction Hepatocellular carcinoma (HCC) is a highly complex and deadly cancer. There is an urgent need for new and effective treatment modalities. Since the primary goal in the management of cancer is to cure and improve survival, personalized therapy can increase survival, reduce mortality rates, and improve quality of life. Biobanks hold potential in leading to breakthroughs in biomedical research and precision medicine (PM). They serve as a biorepository, collecting, processing, storing, and supplying specimens and relevant data for basic, translational, and clinical research. Objective We aimed to highlight the fundamental role of biobanks, harboring high quality, sustainable collections of patient samples in adequate size and variability, for developing diagnostic, prognostic, and predictive biomarkers to develop and PM approaches in the management of HCC. Method We obtained information from previously published articles and BBMRI directory. Results and Conclusion Biobanking of high-quality biospecimens along with patient clinical information provides a fundamental scientific infrastructure for basic, translational, and clinical research. Biobanks that control and eliminate pre-analytical variability of biospecimens, provide a platform to identify reliable biomarkers for the application of PM. We believe, establishing HCC biobanks will empower to underpin molecular mechanisms of HCC and generate strategies for PM. Thus, first, we will review current therapy approaches in HCC care. Then, we will summarize challenges in HCC management. Lastly, we will focus on the best practices for establishing HCC biobanking to support research, translational medicine in the light of new experimental research conducted with the aim of delivering PM for HCC patients.
- 22 November 2021
- Published by Springer Nature in Journal of Gastrointestinal Cancer
- Vol. 52 (4) , 1232-1247
Role of Biobanks for Cancer Research and Precision Medicine in Hepatocellular Carcinoma
Introduction Hepatocellular carcinoma (HCC) is a highly complex and deadly cancer. There is an urgent need for new and effective treatment modalities. Since the primary goal in the management of cancer is to cure and improve survival, personalized therapy can increase survival, reduce mortality rates, and improve quality of life. Biobanks hold potential in leading to breakthroughs in biomedical research and precision medicine (PM). They serve as a biorepository, collecting, processing, storing, and supplying specimens and relevant data for basic, translational, and clinical research. Objective We aimed to highlight the fundamental role of biobanks, harboring high quality, sustainable collections of patient samples in adequate size and variability, for developing diagnostic, prognostic, and predictive biomarkers to develop and PM approaches in the management of HCC. Method We obtained information from previously published articles and BBMRI directory. Results and Conclusion Biobanking of high-quality biospecimens along with patient clinical information provides a fundamental scientific infrastructure for basic, translational, and clinical research. Biobanks that control and eliminate pre-analytical variability of biospecimens, provide a platform to identify reliable biomarkers for the application of PM. We believe, establishing HCC biobanks will empower to underpin molecular mechanisms of HCC and generate strategies for PM. Thus, first, we will review current therapy approaches in HCC care. Then, we will summarize challenges in HCC management. Lastly, we will focus on the best practices for establishing HCC biobanking to support research, translational medicine in the light of new experimental research conducted with the aim of delivering PM for HCC patients.
- Open Access
The Transcription Factor Elf3 Is Essential for a Successful Mesenchymal to Epithelial Transition
The epithelial to mesenchymal transition (EMT) and the mesenchymal to epithelial transition (MET) are two critical biological processes that are involved in both physiological events such as embryogenesis and development and also pathological events such as tumorigenesis. They present with dramatic changes in cellular morphology and gene expression exhibiting acute changes in E-cadherin expression. Despite the comprehensive understanding of EMT, the regulation of MET is far from being understood. To find novel regulators of MET, we hypothesized that such factors would correlate with Cdh1 expression. Bioinformatics examination of several expression profiles suggested Elf3 as a strong candidate. Depletion of Elf3 at the onset of MET severely impaired the progression to the epithelial state. This MET defect was explained, in part, by the absence of E-cadherin at the plasma membrane. Moreover, during MET, ELF3 interacts with the Grhl3 promoter and activates its expression. Our findings present novel insights into the regulation of MET and reveal ELF3 as an indispensable guardian of the epithelial state. A better understanding of MET will, eventually, lead to better management of metastatic cancers.
Open AccessThe Transcription Factor Elf3 Is Essential for a Successful Mesenchymal to Epithelial Transition
The epithelial to mesenchymal transition (EMT) and the mesenchymal to epithelial transition (MET) are two critical biological processes that are involved in both physiological events such as embryogenesis and development and also pathological events such as tumorigenesis. They present with dramatic changes in cellular morphology and gene expression exhibiting acute changes in E-cadherin expression. Despite the comprehensive understanding of EMT, the regulation of MET is far from being understood. To find novel regulators of MET, we hypothesized that such factors would correlate with Cdh1 expression. Bioinformatics examination of several expression profiles suggested Elf3 as a strong candidate. Depletion of Elf3 at the onset of MET severely impaired the progression to the epithelial state. This MET defect was explained, in part, by the absence of E-cadherin at the plasma membrane. Moreover, during MET, ELF3 interacts with the Grhl3 promoter and activates its expression. Our findings present novel insights into the regulation of MET and reveal ELF3 as an indispensable guardian of the epithelial state. A better understanding of MET will, eventually, lead to better management of metastatic cancers.